Oxford BioMedica and Mayo Clinic partnered to develop Oxford BioMedica's LentiVector gene delivery technology to treat chronic glaucoma

Mayo Clinic

U.S. / Non-Profit or Major Disease Foundation

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Oxford BioMedica plc

U.K. / Small-Cap Biopharma (<$1 billion)

$79.1m on 11/04/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced